# The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients

> **NCT01397240** · PHASE4 · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 80 (estimated)

## Conditions studied

- Patients Taking Low-dose Aspirin

## Interventions

- **DRUG:** Albis Tab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01397240
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-07
- **Primary completion:** 2012-01
- **Final completion:** 2013-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2012-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01397240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01397240, "The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01397240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*